Molecular Characterization of Treatment Resistance in FLT3 Mutant Pediatric Acute Myeloid Leukemia

被引：0
|
作者：
Mclachlan, Tabitha [1 ,2 ,3 ]
Murray, Heather [1 ,2 ,3 ]
Skerrett-Byrne, David [1 ,2 ,3 ]
Dubois, Oceane [4 ]
Withers, Kaitlin [5 ]
Verrills, Nikki [1 ,2 ,3 ]
Dun, Matthew [1 ,2 ,3 ]
机构：
[1] Univ Newcastle, Prior Res Ctr Canc Res Innovat & Translat, Callaghan, NSW, Australia
[2] Hunter Med Res Inst, New Lambton Hts, NSW, Australia
[3] Univ Newcastle, Sch Biomed Sci & Pharm, Fac Hlth & Med, Callaghan, NSW, Australia
[4] Univ La Rochelle, Inst Technol, La Rochelle, France
[5] Univ Newcastle, Sch Biol, Fac Sci & Informat Technol, Reprod Sci Grp, Callaghan, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP13
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [31] Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors
    Elshoury, Amro
    Przespolewski, Amanda
    Baron, Jeffrey
    Wang, Eunice S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (03) : 273 - 286
  • [32] Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
    Short, Nicholas J.
    Kantarjian, Hagop
    Ravandi, Farhad
    Daver, Naval
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10
  • [33] FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia The Start of an Era?
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Ravandi, Farhad
    Cortes, Jorge
    CANCER, 2011, 117 (15) : 3293 - 3304
  • [34] FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
    Naval Daver
    Sangeetha Venugopal
    Farhad Ravandi
    Blood Cancer Journal, 11
  • [35] FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
    Daver, Naval
    Venugopal, Sangeetha
    Ravandi, Farhad
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [36] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia
    Fathi, Amir T.
    Chen, Yi-Bin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) : 330 - 336
  • [37] Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia
    Gebru, Melat T.
    Atkinson, Jennifer M.
    Young, Megan M.
    Zhang, Lijun
    Tang, Zhenyuan
    Liu, Zhenqiu
    Lu, Pinyi
    Dower, Christopher M.
    Chen, Longgui
    Annageldiyev, Charyguly
    Sharma, Arati
    Kawasawa, Yuka Imamura
    Zhao, Zhongming
    Miller, Barbara A.
    Claxton, David F.
    Wang, Hong-Gang
    BLOOD, 2020, 136 (09) : 1067 - 1079
  • [38] Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia
    Lim, Yiting
    Gondek, Lukasz
    Li, Li
    Wang, Qiuju
    Ma, Haley
    Chang, Emily
    Huso, David L.
    Foerster, Sarah
    Marchionni, Luigi
    McGovern, Karen
    Watkins, David Neil
    Peacock, Craig D.
    Levis, Mark
    Smith, Bruce Douglas
    Merchant, Akil A.
    Small, Donald
    Matsui, William
    SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (291)
  • [39] LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia
    Yu, Zhou
    Du, Jiaying
    Hui, Hui
    Kan, Shaoxin
    Huo, Tongxin
    Zhao, Kai
    Wu, Tao
    Guo, Qinglong
    Lu, Na
    THERANOSTICS, 2021, 11 (01): : 93 - 106
  • [40] FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
    Michael R. Grunwald
    Mark J. Levis
    International Journal of Hematology, 2013, 97 : 683 - 694
12345